AMD

While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.

Researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.

A recently completed non-human primate study of VGX-0111 demonstrated good tolerability, provided strong transgene expression in the targeted region of the retina, and increased production of the lipids whose decline is associated with macular degeneration.

Mohammad Rafieetary, OD, FAAO, shares brief highlights from his 2023 AOA presentation, "AMD updates: Staying current with its landscape," which he co-presented with Jay Haynie, OD, FAAO.

Over the past decade the progress in retinal disease treatments has exploded with increased numbers of approved pharmaceutical compounds, resulting in more options for treating retinal disease with intravitreal agents and more are in the pipeline.

Jeffry Gerson, OD, FAAO, who presented a poster on the Light Site 3 clinical study at the AOA online e-poster event, discusses a promising new treatment for patients with AMD.

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

Acceptance is based on two phase 3 studies that demonstrated early and sustained vision improvement, meeting primary endpoint of non-inferiority compared to aflibercept.

Alvin Liu, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on deep learning and 3D OCT at the ASCRS annual meeting in San Diego.

Efavirenz boosts cholesterol turnover in retina, brain.

Tina Mac Donald, OD, shares highlights from her presentation on living with an untreatable eye disease, which she presented during the 2023 Controversies in Modern Eye Care meeting.

Leo Semes, OD, shares highlights from his presentation on early detection of AMD, which he presented during the 17th annual Controversies in Modern Eye Care.

David Liao, MD, shares highlights from his discussion on evolving treatment strategies for neovascular AMD and DME, during the 17th annual Controversies in Modern Eye Care meeting.

Deborah Ferrington, PhD, shares a brief overview of her presentation on identifying the mechanism responsible for the death of the retinal pigment epithelium.

A look back on what happened in optometry during the week ofMarch 27-March 31.

Imaging can elucidate visual prognosis and disease progression risk.

A look back on what happened in optometry during the week of March 20-March 24.

Investigators evaluated risuteganib for safety and effectiveness in patients with dry AMD.

These disorders account for most of the vision loss in working-age and elderly Americans.

A look back on what happened in optometry during the week of March 10-March 16.

Research shows how life stressors—such as obesity—reprogram immune system cells and make them destructive to the eye as it ages.

A look back on what's happened in optometry during the week of February 25-March 2.

See the results from our recent poll!

A look back on what's happened in optometry during the week of February 18-February 23.

The eye care community is moving toward a more disruption-resistant system of care, from wearable tech to VEGF-eluting implants.

OPT-302 combined with ranibizumab: covering all the VEGF bases for superior visual gains compared with ranibizumab alone in wet AMD

Vote in our most recent poll!

Advances in drug creation would reduce cost burden of treatment for patients.